A Phase I Study of VS-4718, a Focal Adhesion Kinase Inhibitor, in Subjects With Metastatic Non-Hematologic Malignancies
Phase of Trial: Phase I
Latest Information Update: 03 May 2018
Price : $35 *
At a glance
- Drugs VS 4718 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Verastem Oncology
- 31 Aug 2018 Biomarkers information updated
- 03 May 2018 According to a Verastem Oncology media release, Verastem changed its name to Verastem Oncology.
- 25 Jul 2017 Status changed from active, no longer recruiting to discontinued.